Related Experiment Videos
Nateglinide therapy for type 2 diabetes mellitus
T L Levien1, D E Baker, R K Campbell
1College of Pharmacy, Washington State University, Spokane 99201-3899, USA. levient@wsu.edu
The Annals of Pharmacotherapy
|November 29, 2001
Summary
Nateglinide is a new oral antidiabetic drug that helps control blood sugar by stimulating insulin release. It offers rapid action for post-meal glucose spikes with a lower risk of hypoglycemia compared to other treatments.
Area of Science:
- Pharmacology and Therapeutics
- Endocrinology
- Diabetes Management
Background:
- Nateglinide is a novel nonsulfonylurea oral antidiabetic agent.
- It functions by stimulating insulin secretion from the pancreas.
Purpose of the Study:
- To review the pharmacology, pharmacokinetics, dosing, adverse effects, drug interactions, and clinical efficacy of nateglinide.
- To evaluate nateglinide's role in managing type 2 diabetes.
Main Methods:
- Comprehensive literature search of MEDLINE, Institute for Scientific Information Web of Science, and American Diabetes Association abstracts.
- Inclusion of nateglinide product information and published clinical studies.
Main Results:
- Nateglinide demonstrates a rapid onset and short duration of action, effective in reducing postprandial hyperglycemia.
- Monotherapy with nateglinide improved glycemic control in treatment-naive patients.
- Combination therapy with metformin showed enhanced glycemic control.
Conclusions:
- Nateglinide offers a faster onset and shorter duration of action compared to repaglinide, with less need for dosage titration.
- Its pharmacodynamics suggest a more rapid, shorter insulin secretory response than repaglinide.
- Nateglinide is associated with a potentially lower risk of postabsorptive hypoglycemia than sulfonylureas or repaglinide.